

Registered & Corporate Office :

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5, Opp. SBI Executive Enclave, Banjara Hills, Hyderabad - 500 034, Telangana, INDIA.

Tel: +91-40-2525 9999, Fax: +91-40-2525 9889

CIN: L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 08th November, 2023

To,

The Manager, Corporate Filings Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Security Code: 532815

**Symbol: SMSPHARMA** 

Dear Sir/Madam,

Sub: Disclosure of Related Party Transactions for the half year ended 30<sup>th</sup> September, 2023

Pursuant to Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the details on Related Party Transactions for the half year ended 30th September, 2023 as per the specified format.

This is for your information and records.

Thanking you,

Yours faithfully

For SMS Pharmaceuticals Limited

Thirumalesh Tumma Company Secretary

Encl: a/a

## SMS PHARMACEUTICALS LIMITED

## Disclosure of Related Party Transactions for the half year ended 30th September 2023 (Rs. in Lakhs) Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. Sr Details of the party (listed Details of the counterparty Value of the related Value of In case monies are due to either party Type of related party In case any financial indebtedness is Details of the loans, inter-corporate deposits, advances or investments entity /subsidiary) party transaction as transaction as a result of the transaction incurred to make or give loans, interentering into the approved by the during the corporate deposits, advances or transaction audit committee reporting period investments Nature of Nature (loan/ Purpose for Relationship of the advance/ interindebtedness which the funds counterparty with the Interest Secured/un (loan/issuance of Name PAN Name PAN Opening balance Closing balance Cost tenure corporate will be utilised by Tenure listed entity or its Rate (%) secured debt/ any other deposit/ the ultimate subsidiary etc.) investment recipient Sale of goods 14,750.00 1,100.34 1,072.33 699.00 VKT Pharma Private Associate Company Purchase of goods 200,00 Limited Rent Received 50.00 13.07 13.65 2.01 SMS Lifesciences India Promoters holding 2 Limited more than 10 % of Purchase of goods 2,000.00 286.86 -540.99 -237.39 total equity Raghavendra 191.79 Purchase of goods 1.500.00 -12.76 84.36 Engineering Industries 3 Relative of Promoter SMS Private Limited Sale of goods 150.00 harmaceutical Eshwar Coal Movers Limited Relative of Promoter Purchase of goods 500,00 19,26 -64.80 -6.09 Key Management 152.43 Ramesh Babu Potluri Remuneration Paid 10.30 11.30 Personnel Key Management Vamsi Krishna potluri Remuneration Paid 33.20 0.32 2.07 Personnel Key Management 7 Lakshmi Narayana T Remuneration Paid 11.66 1.75 1.53 Personnel

7.66

0.97

1.02

## Notes:

Thirumalesh T

- 1.The value of the related party transactions with VKT Pharma Private Limited, the amount approved by the Audit Committe/ Board of Directors/ Shareholders of SMS Pharmaceuticals Limited for the period from the conculsion of the 34th AGM held in the year 2022 to till the conclusion of the 35th AGM held in the year 2023.
- 2. The PAN details are not to be included in the disclosure pursuant to guidance note issued by the Stock Exchanges.

Key Management

Personnel

Remuneration Paid

- 3. Dividend paid by SMS Pharmaceuticals Limited to related parties is not included in statement above since payment of dividend by a listed company is not a related party transaction as per Regulation 2(1)(zc) of the SEBI LODR Regulations.
- 4. The above statement does not include the Sitting Fee paid to the Directors of SMS Pharmaceuticals Limited

For SMS Pharmaceuticals Limited

Chief Financial Officer